Opposite effects of metabolic syndrome and calorie restriction on thrombotic disease: Heads and tails of the same coin - Resveratrol's role

Metabolic Syndrome and Related Disorders

Volumn 7, Issue 5, 2009, Pages 397-400

  Cacciapuoti, Federico ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RESVERATROL; SIRTUIN 1;

ACUTE HEART INFARCTION; CALORIC RESTRICTION; ENDOTHELIAL DYSFUNCTION; GENE ACTIVATION; HEART LEFT VENTRICLE FUNCTION; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN FUNCTION; RED WINE; REVIEW; THROMBOSIS;

ANIMALS; BLOOD COAGULATION; CALORIC RESTRICTION; FIBRINOLYTIC AGENTS; HUMANS; METABOLIC SYNDROME X; MYOCARDIAL ISCHEMIA; SIRTUINS; STILBENES; THROMBOSIS; VENTRICULAR FUNCTION, LEFT; WINE;

EID: 70350343557     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2008.0057     Document Type: Review

References (37)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among U.S. adults: fi ndings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
2. Grundy SM, Brewer HBJ, Cleeman JI, Smith SCJ, Lenfant C. Defi nition of metabolic syndrome: Report of the National Heart, Lung, and Blood Insitute/American Hearth Association conference on scientifi c issues related to defi nition. Circulation 2004;199:433-438.
3. Luchsinger JA. A work in progress: the metabolic syndrome. Sci Aging Knowl Environ 2006;10:19.
4. Stern M, Williams K, Gonzales-Villalprando C. Does the metabolic syndrome improve identifi cation of individuals at risk of type-2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676-2681.
5. Barzilai N, Gabriely I. Effect og age on the emegence of insulin resistance. In: Hansen B, Shafi r E (eds.) Insulin resistance and Insulin Resistance syndrome, 1st ed, New York: Taylor & Francis; 2002: 337-348.
6. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008;99:995-1000.
7. De Vriese AS, Veurberen TJ, Van de Voorde J, Lambire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000;130:963-974.
8. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
9. Dandona P. Aljada A. Chaudhuri A. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and infl ammation. Circulation 2005;111:1448-1454.
10. Vischer UM. Von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Heamost 2006;4:1186-1193.
11. Blake GS, Ridker PM. C-reactive protein, infl ammation, and coronary risk. Circ Res 2001;89:763-771.
12. Weindruch R, Walford RL. The retardation of Aging and Disease by Dietary Restriction, Spingfi eld, Illinois: Charles C. Thomas; 1988.
13. Juhan-Vague I,Alessi MC, Vague P. Increased plasma plasminogen activator 1 levels: a possibile link between insulin-resistance and atherothrombosis. Diabetologia 1991;34:457-462.
14. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin-resistance sindrome. A. 1500 patients with angina pectoris. Arteriosc Thromb 1993; 13:1865-1873.
15. Minamiyama Y, Bito Y, Takemura S, Takahashi Y, Kodai S, Mizuchi S. Calorie restriction improves cardiovascular riskfactors via reduction of mitochondrial reactive oxygen species in type II diabetic rats. J Pharm Exp Ther 2007;320:535-554.
16. Park JY, Park KG, Kim HJ, Kang HS, Ahn JD, Kim HS, Kim YM, Son SM, Kim IJ, Kim YK. The effects of the overexpression of recombinant uncoupling protein 2 on proliferation, migration and plasminogen activator inhibitor 1 expression in human vascular smooth muscle cells. Diabetologia 2005;48:1022-1028.
17. Park SY, Choi GH, Choi HI, Ryu J, Jung CY, Lee W. Calorie restriction improves whole-body glucose disposal and insulin resistance in association with the increased adipocyte-specifi c GLUT4 expression in Otsuka Long-Evans Tkushima fatty rats. Arch Biochem Biophys 2005;436:276-284.
18. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004;73:417-435.
19. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 2000;14:1021-1026.
20. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 2006;444:868-874.
21. Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J, McDonagh T. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic â-cells. PloS Biol 2006;4:31.
22. Heilbronn LK, de Jonge L, Frisard MI, De Lany JP, Larson-Meyer DE, Rood J. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals. A randomized controlled trial. JAMA 2006;295:1539-1548.
23. Wallerath T, Deckert G, Ternes T. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002;106:1652-1658.
24. Criqui MH, Ringel BL. Does diet or alcohol explain the French paradox? Lancet 1994;344:1719-1723.
25. Marfella R, Cacciapuoti F,Siniscalchi M, Sasso FC,Marchese F, Cinone F, Musacchio E, Marfella LA, Ruggiero L, Chiorazzo G, Liberti D, Chiorazzo G, Nicoletti GF, Saron C, D'Andrea F, Ammendola C, Verza M, Coppola L. Effect of moderate red wine intake on cardiac prognosis after recent acute myocardial infarction of subjects with type 2 diabetes mellitus. Diabet Med 2006;23:974-981.
26. Yang SR, Wright J, Bauer M, Seweryniak K, Kode A, Rahman I. Sirtuin regulates cigarette smoke-induced pro-infl ammatory mediator release in Re A/p53 NF KB in macrophages in vitro and in rat lung in vivo: implications for chronic infl ammation and aging. Am Physiol Lung Cell Mol. Physiol 2007;292:567-576.
27. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H. Resveratrol improves non-alcoholic fatty liver by activating AMP-activated protein kinase. Acta Pharmacol Sin 2008;29:698-706.
28. Kirk R, Deitch JA, Wu JM, Lerea KM. Resveratrol decreases early signaling events in washed platelets but has little effect on platelet in whole blood. Blood Cells Mol Dis 2000;26:144-150.
29. Wang Z, Huang Y, Zou J, Cao K, Xu Y, Wu JM. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 2002;9:77-79.
30. Pinto MC, Garcia-Barrado JA, Macias P. Resveratrol is a potent inhibitor of the dioxygenase activity of lipoxygenase. J Agric Food Chem 1999;47:4842-4846.
31. Szewczuk LM, Forti L, Stivala LA, Penning TM. Resveratrol is a peroxidase-mediaded inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem 2004;279:22727-22737.
32. Lagouge M, Argmann C, Gerhart-Hines Z, Meriane H, Lerin C, Daussin F. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha. Cell 2006;127:1109-1122.
33. Fukao H, Ijiri Y, Miura M. Effect of trans-resveratrol on the thrombogenicity and atherogenicity in apolipoprotein-E-defi - cient and low-density lipoprotein receptor-defi cient mice. Blood Coagul Fibrinolys 2004;15:441-446.
34. Wang Z, Zou J, Huang Y, Cao K, Xu Y, Wu JM. Effect of resveratrol on platelet activation in vivo and in vitro. Chin Med J 2002;115:378-380.
35. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kaira A. Resveratrol improves health and survival of mice on a highcalorie diet. Nature 2006;444:337-342.
36. Walle T, Hsieh F, Delegge MH, Oatis JE Jr, Walle UK. High absorpion but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004;32:1377-1382.
37. Paoletti R, Bolego C, Poli A, Cignarella A. Metabolic syndrome, infl ammation and atherosclerosis. Vasc Heart Risk Manag 2006;2:145-152.